Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANDI-beta: Canagliflozin add-on vs glimepiride in type 2 diabetes mellitus
jRCTs051180036Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Change in disposition index. Started May 2018; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051180036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180036.